Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients by Huygens, S.A. (Simone) et al.
Vol.:(0123456789) 
The European Journal of Health Economics 
https://doi.org/10.1007/s10198-020-01159-y
ORIGINAL PAPER
Early cost‑utility analysis of tissue‑engineered heart valves compared 
to bioprostheses in the aortic position in elderly patients
Simone A. Huygens1,2,3 · Isaac Corro Ramos3 · Carlijn V. C. Bouten4 · Jolanda Kluin5 · Shih Ting Chiu6 · 
Gary L. Grunkemeier6 · Johanna J. M. Takkenberg1 · Maureen P. M. H. Rutten‑van Mölken2,3
Received: 13 March 2019 / Accepted: 7 January 2020 
© The Author(s) 2020
Abstract
Objectives Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in 
elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic 
heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We per-
formed early Health Technology Assessment of hypothetical TEHV in elderly patients (≥ 70 years) requiring surgical (SAVR) 
or transcatheter aortic valve implantation (TAVI) to assess the potential of TEHV and to inform future development decisions.
Methods Using a patient-level simulation model, the potential cost-effectiveness of TEHV compared with bioprostheses 
was predicted from a societal perspective. Anticipated, but currently hypothetical improvements in performance of TEHV, 
divided in durability, thrombogenicity, and infection resistance, were explored in scenario analyses to estimate quality-
adjusted life-year (QALY) gain, cost reduction, headroom, and budget impact.
Results Durability of TEHV had the highest impact on QALY gain and costs, followed by infection resistance. Improved 
TEHV performance (− 50% prosthetic valve-related events) resulted in lifetime QALY gains of 0.131 and 0.043, lifetime 
cost reductions of €639 and €368, translating to headrooms of €3255 and €2498 per hypothetical TEHV compared to SAVR 
and TAVI, respectively. National savings in the first decade after implementation varied between €2.8 and €11.2 million 
(SAVR) and €3.2–€12.8 million (TAVI) for TEHV substitution rates of 25–100%.
Conclusions Despite the relatively short life expectancy of elderly patients undergoing SAVR/TAVI, hypothetical TEHV 
are predicted to be cost-effective compared to bioprostheses, commercially viable and result in national cost savings when 
biomedical engineers succeed in realising improved durability and/or infection resistance of TEHV.
Keywords Early health technology assessment · Patient-level simulation model · Heart valve implantation · Tissue-
engineered heart valves
JEL Classification I18 · I19
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1019 8-020-01159 -y) contains 
supplementary material, which is available to authorized users.
 * Simone A. Huygens 
 huygens@imta.eur.nl
1 Department of Cardiothoracic Surgery, Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands
2 Erasmus School of Health Policy and Management, Erasmus 
University, Rotterdam, The Netherlands
3 Institute for Medical Technology Assessment, Erasmus 
University, Rotterdam, The Netherlands
4 Department of Biomedical Engineering, Eindhoven 
University of Technology, Eindhoven, The Netherlands
5 Department of Cardio-Thoracic Surgery, Academic Medical 
Centre, Amsterdam, The Netherlands
6 Medical Data Research Centre, Providence Health 
and Service, Portland, OR, USA
 S. A. Huygens et al.
1 3
Introduction
Aortic valve disease is the most frequent indication for 
heart valve surgery [1]. Prevalence of aortic valve disease 
is the highest in elderly patients (stenosis 2.8%; regurgita-
tion 2.0%), due to degeneration of the native aortic valve 
[2]. Aortic valve disease can be treated with medication to 
relieve symptoms, but can only be cured with aortic valve 
replacement [3]. The average annual number of patients 
undergoing surgical aortic valve replacement (SAVR) in 
2007–2015 in The Netherlands was 1931 (Adult Cardiac 
Surgery Database [ACSD]). In addition to SAVR, tran-
scatheter aortic valve implantation (TAVI) is a less inva-
sive alternative to replace the aortic valve for patients who 
are deemed inoperable or at high operable risk because of 
comorbidities [3]. In 2013, 809 patients underwent TAVI in 
The Netherlands and this number is expected to increase to 
approximately 3745 patients per year [4, 5]. Due to the age-
ing population and improvements in healthcare, the number 
of aortic valve implantations is only expected to increase 
further, especially in elderly patients [2, 6].
During a TAVI procedure, a balloon or self-expanding 
bioprosthesis is implanted with a catheter through an artery 
most frequently in the groin or underneath the collarbone. 
Surgical heart valve substitutes can be divided into bio-
logical (human or animal donor) and mechanical valves. In 
elderly patients eligible for surgery, bioprostheses (animal 
donor) are preferred because patients’ life expectancy is usu-
ally shorter than the valve’s durability and therefore, patients 
can benefit from the advantages of bioprostheses (e.g., no 
need for lifelong anticoagulation) [3]. However, risk of re-
intervention due to limited durability of bioprostheses is not 
absent in elderly patients and there is an increased risk of 
endocarditis (i.e. infected heart valve) after SAVR and TAVI 
[7, 8].
Tissue-engineered heart valves (TEHV) can potentially 
limit the disadvantages of existing heart valve substitutes 
[6, 9–11]. Lately, emphasis has shifted towards the develop-
ment of in situ TEHV [10]. In this approach, valve-shaped 
scaffolds are implanted in the heart that recruit cells from 
the bloodstream and surrounding tissues and gradually 
transform into a living valve, while the scaffold degrades 
[11]. Ideally, TEHV would remodel themselves and last a 
lifetime in the same way as most native heart valves do. 
Currently, both surgical and transcatheter implantations 
of in situ TEHV are being explored. Preclinical studies on 
TEHV performance in sheep and clinical trials of tissue-
engineered vascular grafts in humans showed promising 
results, but results of a first-in-man clinical trial are not 
available yet [9–12].
As TEHV are still under development, biomedical engi-
neers requested guidance on which aspects of heart valve 
performance they should focus to improve clinical outcomes 
and achieve cost-effectiveness. Further, they wanted to know 
whether elderly patients in need of aortic valve replacement 
would be among the target populations. To guide the further 
development of TEHV, we performed an early (sometimes 
referred to as prospective) Health Technology Assessment 
(HTA) study to predict the potential cost-effectiveness, head-
room and budget impact of hypothetical TEHV compared 
with bioprostheses in elderly patients requiring surgical or 
transcatheter aortic valve implantation using a patient-level 
simulation model.
Methods
The methods and reporting of this study conform to Con-
solidated Health Economic Evaluation Reporting Standards 
(CHEERS, Supplementary material) [13].
Study population
The study population that is simulated was sampled with 
replacement from existing patient databases and comprised 
patients of ≥ 70  years who had an aortic bioprosthetic 
valve implantation, either through SAVR or TAVI. SAVR 
patients were sampled from the ACSD from The Nether-
lands Association for Cardio-Thoracic Surgery (n = 15,405, 
mean ± SD age = 77.0 ± 4.1 years). TAVI patients were sam-
pled from Dutch health insurance claims databases (n = 809, 
mean ± SD age = 81.9 ± 4.9 years) [4]. Supplement 1 pro-
vides more information on the databases and presents patient 
and intervention characteristics of the study populations.
Patient‑level simulation model
We chose a patient-level simulation model (more specifically 
a discrete event simulation (DES) model) over a decision 
tree or cohort state transition model (also known as Markov 
model) because it has the ability to incorporate recurrence 
of events and to “remember patient history” without leading 
to an unmanageable number of health states [14, 15]. The 
patient-level simulation model was based on a published 
conceptual model developed previously (Fig. 1/Supplement 
2) [16]. Figure S1 illustrates the flowchart of the patient-
level simulation model and Table S2 provides an overview 
of the input parameters. The model combines fixed estimates 
and regression equations for different intermediate and final 
outcomes (Table S3).
The model simulation starts with randomly sampling 
25,000 patients from the databases specified above. The 
number of 25,000 sampled patients was required to get 
stable results. For each patient, the model starts with the 
valve implantation. The period after the valve implantation 
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until death is divided into an early (≤ 30 days after the 
intervention) and late period (> 30 days after the interven-
tion) to be in line with guidelines for reporting outcomes 
after cardiac valve interventions [17]. The following 
events are included in our model during the entire simula-
tion (i.e. both as early and late events): stroke, bleeding, 
prosthetic valve dysfunction (structural valve deterioration 
(SVD) and non-structural valve dysfunction; including 
calcification, structural and residual leak, and thickening 
of the prosthetic valve), -thrombosis and -endocarditis. In 
addition, the following events are only included within 
30 days after the intervention (i.e. early events) as it was 
not expected that long-term occurrence would be related to 
the heart valve intervention: myocardial infarction, vascu-
lar complication, arrhythmias/atrial fibrillation, pacemaker 
implantation, renal failure/acute kidney injury. Patients 
can experience multiple early events within 30 days after 
the intervention. Subsequently, time to late events (i.e. 
stroke, bleeding, prosthetic valve dysfunction, -thrombo-
sis and -endocarditis) and death are calculated (independ-
ent of patient and intervention characteristics or patient 
history). Late mortality is divided into mortality directly 
related to valve-related events, background mortality, and 
excess mortality. Excess mortality is the mortality ascribed 
to the potential excess risk of dying of patients after heart 
valve interventions. The event (including death) with the 
lowest predicted time value is considered to occur after 
which the consequences for costs and quality-adjusted life 
years (QALY) are modelled. Then, times to late events 
and death are recalculated. The simulation stops when 
death has the lowest predicted time value of all events or 
when patients die directly after an event. This process is 
repeated for all patients. By combining data of all simu-
lated patients, the average difference in QALYs and costs 
between TEHV and bioprostheses is calculated. The model 
was implemented in R 3.3.2 using RStudio 1.0.136.
Model input and assumptions
Mortality and events
Mortality was divided into early mortality (≤ 30 days), mor-
tality directly related to valve-related events, background 
mortality, and excess mortality. Background mortality was 
obtained for the year 2016 in the Dutch general population 
[18]. Excess mortality was expressed as hazard ratio rela-
tive to background mortality (SAVR: 0.86 [8]; TAVI: 1.50 
(Supplement 3)). This means that background mortality in 
SAVR patients was 14% lower than in the general popula-
tion, probably due to careful selection of relatively healthy 
elderly to undergo SAVR while frail elderly are rejected for 
surgery [8, 19]. Background mortality in TAVI patients was 
50% higher than in the general population, possibly due to 
increased occurrence of comorbidities in TAVI patients [20].
Clinical input parameters are provided in Table 1. Risks 
of early mortality, stroke, renal failure, arrhythmias and 
myocardial infarction within 30 days after SAVR were 
dependent on patient and intervention characteristics, esti-
mated using logistic regression models based on ACSD 
(Supplement 4). All other mortality and events risks and 
Fig. 1  Conceptual model. Adaptations of the original conceptual model are discussed in Supplement 2
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Table 1  Clinical input parameters
SAVR Distribution Source TAVI Distribution Source
Early mortality (%)
After initial intervention 3.9* Multivariate  normal7 ACSD 5.4 Beta (α 65, β 1135) [21]
After re-intervention 9.0* Multivariate  normal7 ACSD 8.63 Uniform (± 10%) [41]
Early events (%)
Stroke 2.5* Multivariate  normal7 ACSD 2.9 Beta (α 58, β 1919) [21]
Myocardial infarction 1.6* Multivariate  normal7 ACSD 1.0 Beta (α 20, β 1983) [21]
Vascular complications – – 8.1 Beta (α 50, β 565) [21]
Bleeding1 4.2 Beta (α 77, β 1761) [8] 8.7 Beta (α 11, β 115) [21]
Arrhythmias/atrial fibril-
lation
41.5* Multivariate  normal7 ACSD 11.0 Beta (α 31, β 249) [21]
Pacemaker implantation (PI) 8.1 Beta (α 4, β 48) [8] 12.2 Beta (α 85, β 610) [21]
Renal failure/acute kidney 
injury
3.4* Multivariate  normal7 ACSD 4.5 Beta (α 10, β 215) [21]
Prosthetic valve 
 dysfunction2
– – Assumption 6.8 Beta (α 30, β 405) [21]
Prosthetic valve thrombosis – – Assumption – – Assumption
Prosthetic valve endocarditis – – Assumption – – Assumption
Late events (%/year ± SD)
 Stroke 0.77 ± 0.28 Lognormal [8] 0.96 ± 0.104 Lognormal [8, 42]
  Probability of dying (%) 44.0 Beta (α 11, β 14) [8] 44.0 Beta (α 11, β 14) [8]
 Bleeding 0.75 ± 0.16 Lognormal [8] 0.95 ± 0.354 Lognormal [8, 42]
  Probability of dying (%) 39.1 Beta (α 18, β 28) [8] 39.1 Beta (α 18, β 28) [8]
 Structural valve deteriora-
tion
Rate: 0.003 ± 0.001;
Shape: 0.124 ± 0.024
Gompertz [8] Lognormal; 
mean log 
2.711 ± 0.379;
SD log 
0.613 ± 0.335
Lognormal [7]
  Probability of dying (%) 17.0 Dirichlet6
(α1 18, α2 45, α3 41)
[43] 17.0 Dirichlet6
(α1 18, α2 45, α3 41)
[43]
  Probability of re-inter-
vention (%)
43.3 [8] 25.0 [7]
   Probability TAVI 6.2 Uniform (6.1–6.3) [5] 100 Assumption
   Probability SAVR 93.8 [5] 0 Assumption
  Probability conservative 
treatment
39.7 58.0 Assumption
   Probability TAVI 61.7 Uniform (42.0–81.7) [5] 0 Assumption
   Probability medical 
treatment
38.3 [5] 100 Assumption
 Nonstructural valve dys-
function
0.47 ± 0.27 Lognormal [8] – Assumption
  Probability of dying (%) 5.0 Dirichlet6
(α1 1, α2 10, α3 15)
[43] – –
  Probability of re-inter-
vention (%)
38.5 [8] –
 Prosthetic valve throm-
bosis
0.12 ± 0.09 Lognormal [8] 0.245 Uniform (± 20%) [44]
  Probability of dying (%) 0.0 Dirichlet6
(α1 0, α2 2, α3 15)
[43] 0.0 Dirichlet6
(α1 0, α2 3, α3 23)
[43]
  Probability of re-inter-
vention (%)
0.12 [45] 0.12 [46]
 Prosthetic valve endocar-
ditis
0.57 ± 0.08 Lognormal [8] 0.54 ± 0.10 Lognormal [21]
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rates were independent of patient and intervention character-
istics or patient history. The occurrence of late events after 
SAVR was based on our previously performed systematic 
review and meta-analysis [8]. The clinical outcomes after 
TAVI were derived from a systematic review performed 
by Gargiulo et al. [21] (Supplement 4). Risks and rates of 
other early events after SAVR and probabilities of re-inter-
vention or death as a direct result of events were derived 
from literature (references in Table 1). Time to SVD after 
SAVR is obtained from a Gompertz distribution fitted to a 
pooled Kaplan–Meier curve [8]. Time to SVD after TAVI is 
obtained from a lognormal distribution fitted to a published 
Kaplan–Meier curve [7]. These distributions had the best fit 
according to visual comparison, log-likelihood and Akaike 
information criterion (Table S12, Figures S2–15). We were 
unable to determine distributions of other events due to lim-
ited data availability; therefore, we assumed constant hazard 
rates using exponential distributions.
Costs
The majority of the healthcare cost inputs were derived 
from our previously performed retrospective cost-analysis 
of Dutch health insurance claims data [4]. Healthcare costs 
were divided into intervention (procedure and hospital 
stay), event, other healthcare (healthcare use not directly 
related to the heart valve intervention or initial treatment 
of associated events), and end-of-life healthcare (healthcare 
use associated with dying) costs (Table 2). Healthcare costs 
were defined as expenditures reimbursed by health insurers. 
Costs were dependent on patient and intervention charac-
teristics using (multilevel) generalised linear models ((M)
GLM) (Table S12/ [4]), except for costs of bleeding and 
conservative treatment of prosthetic valve-related events. We 
assumed most events had a permanent influence on health-
care use (e.g., lifelong follow-up with cardiologist after 
pacemaker implantation). Hence, other healthcare costs were 
assumed to be increased for the remaining patient’s lifetime 
after most events, except for prosthetic valve-related events 
and re-intervention to avoid double counting of follow-up 
costs for the initial heart valve implantation. Other health-
care costs were estimated with the MGLM regression for-
mula within three years after the intervention (Table S9). 
Beyond three years, these costs were adjusted to patient age 
using relative increases in total healthcare costs by age and 
sex of the Dutch general population [22].
Costs beyond healthcare included productivity costs of 
unpaid work and informal care costs and were based on 
results from a patient-reported questionnaire published 
previously [23]. These costs were dependent on patient 
and intervention characteristics based on logistic mod-
els and GLM (Tables S13–14). Productivity costs of paid 
work were excluded because the vast majority (≥ 95%) of 
elderly patients undergoing SAVR or TAVI do not have paid 
employment [23]. Productivity costs were increased after 
events by assuming that patients were unable to perform 
their unpaid work activities during hospital admissions for 
bleeding and prosthetic valve-related events (Table S15), 
Table 1  (continued)
SAVR Distribution Source TAVI Distribution Source
  Probability of dying (%) 34.0 Dirichlet6
(α1 26, α2 37, α3 13)
[43] 34.0 Dirichlet6
(α1 26, α2 37, α3 13)
[43]
  Probability of re-inter-
vention (%)
49.0 [8] 49.0 [8]
 Hazard ratio excess mor-
tality
0.86 Uniform (± 10%) [8] 1.40 Uniform (± 10%) This study
*Mean (95% CI) in the Adult Cardiac Surgery Database (ACSD). Risk in the patient-level simulation model dependent on patient and interven-
tion characteristics using logistic regression formula. “-“Not reported in any of the studies, therefore assumed not to occur
1 Definition of bleeding is reexploration for bleeding after SAVR and major bleedings after TAVI
2 Paravalvular leak after TAVI
3 Hazard ratio of 1.6 applied to early mortality risk of initial intervention
4 Hazard ratio of SAVR patients compared to the general population applied to occurrence in age and sex matched general population for the 
TAVI population
5 Blackstone & Kirklin have shown that valve thrombosis mainly occurs during the first year after surgical mechanical aortic valve implantation 
and deteriorates to almost zero after six years [47]. The higher occurrence in the early phase may be caused by suboptimal anticoagulation treat-
ment in the first post-intervention period. Since, the mean follow-up of the Bern TAVI Registry was only one year, it is likely that the occurrence 
rate of valve thrombosis after TAVI found in this study will not remain constant but will reduce over time. Therefore, we recalculated the lin-
earized occurrence rate of 0.69%/patient-year, assuming that it will be zero from year 7 onwards
6 Dirichlet distribution parameters: α1 = number of deaths, α2 = number of re-interventions, α3 = number of other treatment
7 Multivariate normal distribution: coefficients of the regression model are randomly drawn from a multivariate normal distribution based on 
coefficients and variance–covariance matrix
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Table 2  Costs and utilities
*Mean in the Vektis database adjusted to 2016€. Costs in the model dependent on patient and intervention 
characteristics using (M)GLM [4]
1 Mean total healthcare costs per year including costs of treatment of events and death (costs types are esti-
mated separately in the model), but excluding intervention costs. Costs are based on data of SAVR patients, 
but it is assumed they are also applicable to TAVI patients
2 Conservative treatment, no re-intervention
3 Mean across all patients, including patients without unpaid work or informal care
4 Multivariate normal distribution: coefficients of the regression model are randomly drawn from a multi-
variate normal distribution based on coefficients and variance–covariance matrix
5 50% deviation of 1-utility multiplier to prevent the utility multiplier from exceeding 1
Distribution Source
Intervention costs
SAVR 25,474 Multivariate  normal4 [4]*
TAVI 33,178 Multivariate  normal4 [4]*
Event treatment costs
Stroke 3054 Multivariate  normal4 [4]*
Myocardial infarction 5157 Multivariate  normal4 [4]*
Vascular complications 5112 Uniform (∓ 20%) [48]
Reexploration for bleeding 5048 Uniform (∓ 20%) [48]
Bleeding 1617 Uniform (∓ 20%) [48]
Atrial fibrillation (without PI) 1225 Multivariate  normal4 [4]*
Pacemaker implantation (PI) 11,738 Multivariate  normal4 [4]*
Acute kidney injury/renal failure 9650 Multivariate  normal4 [4]*
Prosthetic valve dysfunction 1478 Uniform (∓ 20%) [49–54]
Prosthetic valve thrombosis 5824 Uniform (∓ 20%) [53–55]
Prosthetic valve endocarditis 8923 Multivariate  normal4 [4]*
Re-intervention SAVR 25,936 Multivariate  normal4 [4]*
Re-intervention TAVI 33,178 Multivariate  normal4 [4]*
Other healthcare cost1
Post-intervention year 1 18,479 Multivariate  normal4 [4]*
Post-intervention year 2 10,607 [4]*
Post-intervention year 3 10,832 [4]*
Productivity costs of unpaid work3 Costs per month
SAVR 44 Multivariate  normal4 [23]
TAVI 50 Multivariate  normal4 [23]
Informal care costs3 Costs per month
SAVR 164 Multivariate  normal4 [23]
TAVI 388 Multivariate  normal4 [23]
Utilities at start of the simulation
SAVR 0.837 Multivariate  normal4 [23]
TAVI 0.718 Multivariate  normal4 [23]
Utilities after events Utility multiplier Duration
Stroke 0.841 Lifetime Uniform5 [56, 57]
Myocardial infarction 0.914 1 year Uniform5 [58, 59]
Vascular complications 0.981 1 week Uniform5 [60]
Bleeding 0.965 1 year Uniform5 [61]
Atrial fibrillation (without PI) 0.955 1 year Uniform5 [62]
Pacemaker implantation (PI) 0.804 1 month Uniform5 [63]
Acute kidney injury/renal failure 0.804 1 year Uniform5 [64]
Re-intervention 0.946 SAVR/TAVI:
4/1 month(s)
Uniform5 [65]/[8]
Conservative treatment of:
 Prosthetic valve dysfunction 0.8862 Lifetime Uniform5 [50, 66]
 Prosthetic valve thrombosis 0.9682 10 days Uniform5 [55, 67]
 Prosthetic valve endocarditis 0.9682 6 weeks Uniform5 [67, 68]
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4 months after surgical re-intervention [23], 1 month after 
transcatheter re-intervention [23], and 28.2 days after stroke 
[24]. Informal care costs were assumed to be unchanged 
after in-hospital treatment of bleeding and prosthetic valve-
related events, because care associated with these events 
is provided in-hospital. After re-intervention, we assumed 
equal informal care costs as after the initial intervention. 
After stroke, we assumed that 54% of patients used informal 
care for 13.5 h/week during the first half year and 8.3 h/week 
during the second half year and subsequent years [24].
Health‑related quality of life
Health-related quality of life was expressed in utilities. Util-
ity of patients without complications was measured with the 
EQ-5D-5L and dependent on patient and intervention char-
acteristics using regression formulas (more details provided 
in our previous publication [23]). The utility was corrected 
for events using utility multipliers derived from the literature 
for a specific time duration after the event based on literature 
or assumptions (Table 2). Even when patients did not experi-
ence events, their utility changed over time due to ageing. 
During the first 6 years after the intervention, utility was cal-
culated using a regression formula including time-dependent 
variables [25]. Beyond year six, yearly absolute disutilities 
of the general population (males:0.00128; females:0.00171) 
were subtracted from the predicted utility [26].
Tissue‑engineered heart valves
Exact costs and performance of TEHV are unclear, because 
TEHV are not yet in clinical use. Therefore, we had to make 
a number of assumptions on hypothetical TEHV perfor-
mance and costs, informed by discussions with a research 
consortium (1Valve) working on the development of in situ 
TEHV, including biomedical engineers and cardiothoracic 
surgeons. First, we assumed that TEHV will not be intro-
duced into clinical practice until their safety has been estab-
lished. For this reason, we did not include any scenarios in 
which the risks of early mortality or valve-related events 
were higher than with current heart valve replacements. The 
procedure to implant TEHV is expected to be comparable 
to implanting existing heart valve substitutes. Hence, we 
assumed that early mortality and event risks, which are 
mainly procedure related and not valve related, are compa-
rable to bioprostheses used for SAVR or TAVI. Further, we 
assumed that probabilities to die or undergo re-intervention 
after early and late events were comparable to bioprostheses. 
Based on expert opinion and aspects on which the ongo-
ing development of TEHV focuses, we investigated three 
types of improvements that influence the occurrence of late 
events: (1) Improved durability due to lower rates of pros-
thetic valve dysfunction (SVD and non-structural valve dys-
function; including calcification, structural and residual leak, 
and thickening of the prosthetic valve) resulting in longer 
time to re-intervention; (2) Reduced thrombogenicity, the 
tendency of heart valve substitutes in contact with blood 
to produce a thrombus or clot, resulting in lower rates of 
prosthetic valve thrombosis and reduced need for anticoagu-
lation treatment; (3) Improved infection resistance resulting 
in lower rates of endocarditis and subsequent hospitalisation 
and/or re-intervention.
Analyses
Cost-effectiveness analyses were performed in a Dutch set-
ting from a societal perspective applying a lifetime horizon 
with costs expressed in 2016 Euros and effects in QALYs. 
Future health benefits and costs were discounted with 1.5% 
and 4%, respectively, according to Dutch HTA guidelines 
[27].
Several scenario analyses were performed to estimate the 
impact of variations in hypothetical TEHV performance on 
costs, effects, and cost-effectiveness assuming that the price 
of TEHV is equal to that of bioprostheses (SAVR:€2500; 
TAVI:€18,000). First, we performed scenario analyses 
where durability, thrombogenicity, and infection resistance 
of TEHV were varied separately with varying rates, com-
pared to bioprostheses. Further, three scenario analyses, in 
which these three types of improvements were varied simul-
taneously, were performed (Table 3). In the first combined 
scenario, the ‘perfect performance’ scenario, we assumed 
perfect durability, no thrombogenicity, and perfect infection 
resistance of TEHV in which the occurrence of prosthetic 
Table 3  Occurrence of valve-
related events with TEHV 
compared to bioprostheses
Bold: large improvement in TEHV performance, Bold italic: moderate improvement in TEHV perfor-
mance, Italic: moderate deterioration in TEHV performance
Combined scenarios Long-term valve-related events
Prosthetic valve 
dysfunction (%)
Prosthetic valve 
thrombosis (%)
Prosthetic valve 
endocarditis (%)
Stroke Bleeding
Perfect performance − 100 − 100 − 100 Equal Equal
Improved performance − 50 − 50 − 50 Equal Equal
Partial improved performance + 50 − 50 − 50 Equal Equal
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valve-related events was equal to the level in the general 
population (i.e. zero). In the second combined scenario, the 
‘improved performance’ scenario, we assumed improved 
durability, reduced thrombogenicity, and improved infec-
tion resistance of TEHV in which the occurrence of pros-
thetic valve-related events was reduced by 50% compared 
to bioprostheses. In the final combined scenario, the ‘par-
tial improved performance’ scenario, we assumed reduced 
thrombogenicity and improved infection resistance (i.e. 
events related to thrombogenicity and infection resistance 
were reduced with 50%), but reduced durability of TEHV 
(i.e. prosthetic valve dysfunction events increased by 50%) 
compared to bioprostheses. In all scenarios, occurrence 
rates of strokes and bleedings were not varied because these 
events are influenced by anticoagulation treatment which 
is only prescribed for patients after aortic valve implanta-
tion with bioprostheses during the first 3 months after the 
intervention and is likely to be prescribed for TEHV as well. 
[3] Hypothetical TEHV were compared to bioprostheses 
implanted using the same approach: either surgical (SAVR) 
or transcatheter (TAVI) implantation. In the remainder, 
SAVR and TAVI refer to the comparator treatment, i.e. heart 
valve implantations with bioprostheses. The ‘improved per-
formance’ scenario was perceived as the most realistic sce-
nario and was, therefore, used in several additional analyses. 
Subgroup analyses were performed for patients aged 70–80 
and > 80 years for the ‘improved performance’ scenario. For 
all scenarios, we calculated incremental costs, effects, cost-
effectiveness ratio (ICER) and headroom.
The headroom is the maximum cost of TEHV to remain 
cost-effective compared to bioprostheses when applying a 
cost-per-QALY threshold (SAVR:€20,000; TAVI:€50,000). 
Different thresholds for SAVR and TAVI were applied, 
because in The Netherlands, this threshold depends on dis-
ease burden with current standard of care; the higher the dis-
ease burden, the higher the cost-per-QALY threshold [28]. 
Disease burden was expressed in proportional shortfall (i.e. 
fraction of QALYs that people lose relative to their remain-
ing life expectancy when untreated) which can take a value 
between 0 (minimal burden of disease) and 1 (maximum 
burden of disease) and was calculated with the iMTA Dis-
ease Burden Calculator [29, 30]. The disease burden was 
0.19 in SAVR and 0.48 in TAVI patients.
Probabilistic sensitivity analysis (PSA) was performed 
for the ‘improved performance’ and ‘partially improved 
performance’ scenarios. PSA was implemented as a double 
loop: an inner loop, in which 500 patients were sampled 
with replacement, and an outer loop in which 500 sets of 
input parameters values of the model were randomly drawn 
(Supplement 6). For each set of coefficients, mean outcomes 
over all patients were recorded and the mean and credible 
interval (i.e. 2.5% and 97.5% percentiles) over all 500 mean 
values for each outcome were calculated. The incremental 
costs and effects of hypothetical TEHV compared to exist-
ing heart valves were plotted in cost-effectiveness planes 
and probabilities that the intervention was cost-effective at 
certain cost-per-QALY thresholds were displayed in cost-
effectiveness acceptability curves (CEAC). The results of the 
PSA are used to calculate the expected value of perfect infor-
mation (EVPI) for the ‘improved performance’ and ‘partially 
improved performance’ scenarios. The EVPI is calculated 
as the difference between the expected value of the deci-
sion made assuming perfect information and the decision 
made using current information [31]. EVPI is presented at 
the cost-per-QALY threshold for the specific intervention 
(SAVR: €20,000; TAVI: €50,000).
Budget impact reflects the difference in total population-
level costs of SAVR or TAVI with bioprostheses compared 
to hypothetical TEHV. Budget impact analyses were per-
formed for the ‘improved performance’ scenario for the 
first 10 years after introduction of TEHV. Differences in 
population-level costs were calculated by multiplying the 
differential total costs per patient with the expected number 
of TEHV candidates, assuming substitution rates of 25, 50, 
75 or 100% of bioprostheses by TEHV. The expected annual 
number of SAVR patients was 1931 patients, based on the 
average annual number of SAVR recorded in the ACSD 
between 2007 and 2015. The expected annual number of 
TAVI patients was 809 or 3745 patients, based on the aver-
age annual number of TAVIs recorded in the Dutch health 
insurance claims database in 2013 and estimations of Durko 
et al., respectively [4, 5].
Validation
Extensive internal validation was performed to check the 
model’s performance using the TECH-VER checklist [32]. 
External validation was conducted comparing survival and 
time-to-events derived from our model (applying US sur-
vival tables for background mortality [33]) with an external 
dataset from the US Providence Health System [34] in four 
subgroups: males and females between 70 and 80 years old 
and males and females > 80 years old. This Portland data-
set contains 2814 patients aged ≥ 70 years who underwent 
SAVR with bioprostheses with 17,525 follow-up years 
(mean 6.2 years). We did not have access to an external 
dataset to validate TAVI outcomes.
Results
Results of the scenario analyses are presented in Table 4. Of 
the three TEHV performance components, durability had 
the highest impact on predicted cost-effectiveness. This is 
emphasised by the results of the ‘partial improved scenario’ 
where the consequences of reductions in durability of TEHV 
Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses…
1 3
Ta
bl
e 
4 
 C
os
t-e
ffe
cti
ve
ne
ss
 re
su
lts
 of
 sc
en
ar
io
 an
aly
se
s LY
QA
LY
s
So
cie
tal
 co
sts
He
alt
hc
ar
e c
os
ts
∆L
Ys
∆Q
AL
Ys
∆S
oc
iet
al 
co
sts
∆H
ea
lth
-
ca
re
 
co
sts
IC
ER
He
ad
ro
om
(C
os
t/Q
AL
Y 
th
re
sh
-
ol
d €
20
,00
0;
50
,00
0)
SA
VR
SA
VR
 w
ith
 ex
ist
in
g v
alv
e p
ro
sth
es
es
10
.19
6
6.7
61
15
0,8
60
13
7,4
47
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 70
–8
0 y
ea
rs
11
.04
7
7.3
58
15
9,9
39
14
5,8
52
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 >
 80
 ye
ar
s
6.9
85
4.4
88
11
4,7
59
10
3,8
14
Im
pr
ov
ed
 du
ra
bi
lit
y o
f T
EH
V
 N
o p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
10
.34
8
6.8
90
14
9,4
40
13
6,8
13
0.1
52
0.1
29
− 
14
20
− 
63
4
–
40
04
 75
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
10
.31
7
6.8
61
14
9,7
80
13
6,9
94
0.1
21
0.1
01
− 
10
80
− 
45
3
–
30
94
 50
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
10
.28
0
6.8
30
15
0,1
05
13
7,1
32
0.0
84
0.0
69
− 
75
6
− 
31
5
–
21
34
 25
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
10
.24
5
6.8
00
15
0,5
22
13
7,3
29
0.0
49
0.0
40
− 
33
8
− 
11
8
–
11
30
Re
du
ce
d t
hr
om
bo
ge
ni
cit
y o
f T
EH
V
 N
o v
alv
e t
hr
om
bo
sis
 ev
en
ts
10
.19
6
6.7
61
15
0,7
58
13
7,3
69
0.0
01
0.0
00
− 
10
2
− 
79
–
11
0
 75
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
10
.19
6
6.7
61
15
0,7
92
13
7,3
95
0.0
00
0.0
00
− 
69
− 
53
–
75
 50
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
10
.19
6
6.7
61
15
0,8
16
13
7,4
14
0.0
00
0.0
00
− 
44
− 
33
–
50
 25
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
10
.19
6
6.7
61
15
0,8
27
13
7,4
21
0.0
00
0.0
00
− 
34
− 
26
–
38
Im
pr
ov
ed
 in
fec
tio
n r
es
ist
an
ce
 of
 T
EH
V
 N
o e
nd
oc
ar
di
tis
 ev
en
ts
10
.36
1
6.8
77
15
1,1
18
13
7,9
38
0.1
65
0.1
16
25
7
49
1
22
22
20
61
 75
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
10
.32
3
6.8
50
15
1,1
09
13
7,8
65
0.1
27
0.0
89
24
8
41
8
27
92
15
30
 50
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
10
.28
3
6.8
21
15
1,0
30
13
7,7
29
0.0
87
0.0
61
17
0
28
2
27
97
10
44
 25
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
10
.23
5
6.7
88
15
0,8
89
13
7,5
30
0.0
39
0.0
28
28
83
10
28
52
6
Pe
rfe
ct 
du
ra
bi
lit
y, 
no
 th
ro
m
bo
ge
ni
cit
y, 
an
d p
er
fec
t 
in
fec
tio
n r
es
ist
an
ce
 (n
o e
ve
nt
s)
10
.51
6
7.0
10
14
9,5
17
13
7,2
19
0.3
20
0.2
49
− 
13
44
− 
22
8
–
63
22
Im
pr
ov
ed
 du
ra
bi
lit
y, 
re
du
ce
d t
hr
om
bo
ge
ni
cit
y, 
an
d i
m
pr
ov
ed
 in
fec
tio
n r
es
ist
an
ce
 (5
0%
 le
ss
 
ev
en
ts)
10
.36
8
6.8
92
15
0,2
21
13
7,3
83
0.1
72
0.1
31
− 
63
9
− 
65
–
32
55
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 70
–8
0 y
ea
rs
11
.24
8
7.5
12
15
9,3
97
14
5,9
68
0.2
01
0.1
54
− 
54
2
11
5
–
36
16
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 >
 80
 ye
ar
s
7.0
65
4.5
45
11
4,1
61
10
3,4
36
0.0
79
0.0
57
− 
59
8
− 
37
8
–
17
40
De
cr
ea
se
d d
ur
ab
ili
ty
 (5
0%
 m
or
e e
ve
nt
s) 
bu
t 
re
du
cti
on
 in
 th
ro
m
bo
ge
ni
cit
y a
nd
 im
pr
ov
em
en
t 
in
 in
fec
tio
n r
es
ist
an
ce
 (5
0%
 le
ss
 ev
en
ts)
10
.22
0
6.8
14
15
2,2
78
13
8,4
52
0.0
24
0.0
53
14
17
10
05
26
,84
1
− 
36
1
TA
VI
TA
VI
 w
ith
 ex
ist
in
g v
alv
e p
ro
sth
es
es
5.6
79
3.1
34
10
0,2
43
81
,20
2
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 70
–8
0 y
ea
rs
8.0
00
4.0
89
12
0,1
95
94
,01
0
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 >
 80
 ye
ar
s
4.4
35
2.6
30
89
,88
8
74
,62
6
Im
pr
ov
ed
 du
ra
bi
lit
y o
f T
EH
V
 N
o p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
5.7
54
3.1
82
99
,66
5
80
,61
6
0.0
74
0.0
48
− 
57
8
− 
58
6
–
15
40
; 2
98
3
 S. A. Huygens et al.
1 3
Ta
bl
e 
4 
 (c
on
tin
ue
d)
LY
QA
LY
s
So
cie
tal
 co
sts
He
alt
hc
ar
e c
os
ts
∆L
Ys
∆Q
AL
Ys
∆S
oc
iet
al 
co
sts
∆H
ea
lth
-
ca
re
 
co
sts
IC
ER
He
ad
ro
om
(C
os
t/Q
AL
Y 
th
re
sh
-
ol
d €
20
,00
0;
50
,00
0)
 75
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
5.7
39
3.1
72
99
,83
4
80
,77
1
0.0
60
0.0
39
− 
41
0
− 
43
0
–
11
80
; 2
33
5
 50
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
5.7
21
3.1
60
99
,97
0
80
,90
2
0.0
42
0.0
27
− 
27
3
− 
30
0
–
80
7;
 16
08
 25
% 
les
s p
ro
sth
eti
c v
alv
e d
ys
fu
nc
tio
n e
ve
nt
s
5.7
02
3.1
48
10
0,1
04
81
,04
5
0.0
23
0.0
14
− 
13
9
− 
15
6
–
42
3;
 84
9
Re
du
ce
d t
hr
om
bo
ge
ni
cit
y o
f T
EH
V
 N
o v
alv
e t
hr
om
bo
sis
 ev
en
ts
5.6
80
3.1
34
10
0,1
21
81
,09
2
0.0
00
0.0
00
− 
12
2
− 
11
0
–
12
6;
 13
2
 75
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
5.6
80
3.1
34
10
0,1
56
81
,12
3
0.0
00
0.0
00
− 
87
− 
79
–
91
; 9
7
 50
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
5.6
80
3.1
34
10
0,1
80
81
,14
5
0.0
00
0.0
00
− 
64
− 
57
–
66
; 6
9
 25
% 
les
s v
alv
e t
hr
om
bo
sis
 ev
en
ts
5.6
79
3.1
34
10
0,2
08
81
,17
0
0.0
00
0.0
00
− 
35
− 
31
–
35
; 3
5
Im
pr
ov
ed
 in
fec
tio
n r
es
ist
an
ce
 of
 T
EH
V
 N
o e
nd
oc
ar
di
tis
 ev
en
ts
5.7
42
3.1
64
10
0,1
79
81
,07
4
0.0
63
0.0
30
− 
64
− 
12
8
–
66
8;
 15
74
 75
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
5.7
29
3.1
57
10
0,2
17
81
,12
1
0.0
50
0.0
24
− 
26
− 
81
–
50
2;
 12
16
 50
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
5.7
13
3.1
49
10
0,2
18
81
,14
6
0.0
33
0.0
16
− 
25
− 
55
–
34
1;
 81
5
 25
% 
les
s e
nd
oc
ar
di
tis
 ev
en
ts
5.6
92
3.1
40
10
0,2
05
81
,15
5
0.0
13
0.0
06
− 
38
− 
47
–
16
6;
 35
8
Pe
rfe
ct 
du
ra
bi
lit
y, 
no
 th
ro
m
bo
ge
ni
cit
y, 
an
d p
er
fec
t 
in
fec
tio
n r
es
ist
an
ce
 (n
o e
ve
nt
s)
5.8
17
3.2
13
99
,45
4
80
,36
6
0.1
37
0.0
79
− 
78
9
− 
83
6
–
23
67
; 4
73
4
Im
pr
ov
ed
 du
ra
bi
lit
y, 
re
du
ce
d t
hr
om
bo
ge
ni
cit
y, 
an
d i
m
pr
ov
ed
 in
fec
tio
n r
es
ist
an
ce
 (5
0%
 le
ss
 
ev
en
ts)
5.7
55
3.1
76
99
,87
5
80
,78
6
0.0
75
0.0
43
− 
36
8
− 
41
6
–
12
20
; 2
49
8
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 70
–8
0 y
ea
rs
8.1
56
4.1
74
11
9,8
25
93
,52
6
0.1
56
0.0
86
− 
37
0
− 
48
5
–
20
82
; 4
65
0
 S
ub
gr
ou
p p
ati
en
ts 
ag
ed
 >
 80
 ye
ar
s
4.4
74
2.6
52
89
,55
7
74
,26
1
0.0
38
0.0
23
− 
33
1
− 
36
5
–
78
3;
 14
61
De
cr
ea
se
d d
ur
ab
ili
ty
 (5
0%
 m
or
e e
ve
nt
s) 
bu
t 
re
du
cti
on
 in
 th
ro
m
bo
ge
ni
cit
y a
nd
 im
pr
ov
em
en
t 
in
 in
fec
tio
n r
es
ist
an
ce
 (5
0%
 le
ss
 ev
en
ts)
5.6
66
3.1
39
10
0,9
04
81
,58
6
− 
0.0
14
0.0
05
66
0
38
5
12
2,2
76
; 7
1,2
25
− 
55
2;
 −
 39
0
‘–
‘T
EH
V 
do
m
in
ate
s. 
LY
 li
fe 
ye
ar
s, 
Q
AL
Y 
qu
ali
ty
-a
dj
us
ted
 li
fe 
ye
ar
s, 
IC
ER
 in
cr
em
en
tal
 co
st-
eff
ec
tiv
en
es
s r
ati
o, 
W
TP
 w
ill
in
gn
es
s t
o 
pa
y 
pe
r Q
AL
Y 
ga
in
ed
 in
 E
ur
os
, S
AV
R 
su
rg
ica
l a
or
tic
 v
alv
e 
re
pl
ac
em
en
t, 
TA
VI
 tr
an
sc
ath
ete
r a
or
tic
 va
lve
 im
pl
an
tat
io
n, 
TE
H
V 
tis
su
e-
en
gi
ne
er
ed
 he
ar
t v
alv
es
Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses…
1 3
for the predicted cost-effectiveness could not be offset by 
reduction in thrombogenicity and improvement of infection 
resistance of TEHV. The ‘perfect performance’ scenario pro-
vides insight in the maximum predicted lifetime QALY gain 
and cost savings of TEHV: 0.249 QALYs and €1344 ver-
sus SAVR and 0.079 QALYs and €789 versus TAVI. In the 
‘improved performance’ scenario, lifetime QALY gains of 
0.131 and 0.043, lifetime cost reductions of €639 and €368, 
translating to headrooms of €3255 and €2498 per TEHV 
compared to SAVR or TAVI, respectively, were predicted. 
The median predicted SVD-free life expectancy increased 
from 9.4 after SAVR to 10.0 years with TEHV and from 4.6 
after TAVI to 4.7 years with TEHV (Table S16). Subgroup 
analyses showed that predicted QALY gain was higher in 
patients 70–80 years than in patients > 80 years old, while 
cost reductions were comparable.
In the PSA of the ‘improved performance’ scenario, pre-
dicted incremental costs and effects varied as shown in the 
cost-effectiveness plane (Fig. 2a), with most data points 
lying in the south-east quadrant, suggesting QALY gains at 
lower costs. The CEACs show that when applying a thresh-
old of €20,000 per QALY, there is a probability of cost-
effectiveness of 100% for TEHV compared with SAVR and 
99% for TEHV compared with TAVI (Fig. 2b). The results 
of the PSA of the ‘partially improved performance’ scenario 
are provided in Figure S16. The EVPI in both the ‘improved 
performance’ and ‘partially improved performance’ scenar-
ios is relatively low. At a willingness to pay threshold of 
€20,000, the EVPI is €3149 per patient in the ‘improved 
performance scenario’ and €60 for in the ‘partially improved 
performance scenario’ for TEHV compared to SAVR. At a 
willingness to pay threshold of €50,000, the EVPI is €2873 
per patient in the ‘improved performance scenario’ and 
€119 in the ‘partially improved performance scenario’ for 
TEHV compared to TAVI. This can be explained by the fact 
that there is low uncertainty about the cost-effectiveness of 
TEHV in the ‘improved performance’ scenario (i.e. high 
probability of being cost-effective) and in the ‘partially 
improved performance’ scenario (i.e. low probability of 
being cost-effective). As a result, additional information on 
the input parameters is unlikely to change the reimburse-
ment decision.
Figure 3 (Table S17) shows that implementing SAVR and 
TAVI with TEHV (in the ‘improved performance’ scenario) 
instead of bioprostheses resulted in predicted cost savings 
of the Dutch healthcare budget in the next 10 years varying 
Fig. 2  Probabilistic sensitivity analyses outcomes of surgical (SAVR) 
and transcatheter (TAVI) aortic valve implantation with TEHV (50% 
improved performance) compared to bioprostheses. a Cost-effective-
ness plane. b Cost-effectiveness acceptability curve (CEAC)
Fig. 3  Cumulative cost savings in the first 10  years after introduction of surgical (SAVR; left) and transcatheter (TAVI; right) aortic valve 
implantation with TEHV (‘improved performance’ scenario) compared to bioprostheses
 S. A. Huygens et al.
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between €2.8–€11.2 (SAVR) and €3.2–€12.8(TAVI) million, 
for TEHV substitution rates of 25% or 100%.
The predicted headroom of TEHV compared to SAVR 
and TAVI, respectively, varied from €38 and 35 if TEHV 
would only result in a small reduction in thrombogenicity to 
€6322 and 4734 if there would be no prosthetic valve-related 
events at all using TEHV (Table 4).
Extensive internal validation was performed to check the 
model’s performance using the TECH-VER checklist [32]. 
Further, Kaplan–Meier curves of survival and time to SVD 
that were used as input were comparable to curves derived 
from the model (Supplement 8) [8]. External validation of 
the model’s survival output with the Portland dataset showed 
that results were comparable, but the model predicted a 
slightly higher survival, especially in females between 70 
and 80 years old (Supplement 9). There were discrepan-
cies between cumulative incidence functions of events; the 
number of events in the model was higher than observed in 
Portland (Supplement 9).
Discussion
This early HTA study showed that hypothetical TEHV are 
likely to be cost-effective when used in elderly patients with 
aortic valve disease, under the current assumptions about 
improvements, compared to bioprostheses [2]. Improve-
ments in durability of TEHV had the greatest impact on 
cost-effectiveness. Improved durability not only increased 
lifetime QALYs, but also reduced costs. In addition, it is 
worthwhile to pursue improved infection resistance, con-
sidering the lifetime QALY gains that can be achieved 
with acceptable costs when prosthetic valve endocarditis is 
prevented. Reductions in thrombogenicity are unlikely to 
significantly impact cost-effectiveness of TEHV in elderly 
patients. In these patients, reduced thrombogenicity only 
reduces valve thrombosis occurrence, since lifelong anti-
coagulation treatment is not required with bioprostheses 
or patients already use anticoagulation treatment for other 
indications (resulting in less strokes and more bleedings than 
in the general population) [8]. However, reduced thrombo-
genicity may have more impact on cost-effectiveness of 
TEHV in younger patients who are eligible for mechanical 
valves and often have no other indication for anticoagulation 
treatment as reduced thrombogenicity would not only reduce 
valve thrombosis and strokes, but also the need of lifelong 
anticoagulation associated with increased bleedings. Finally, 
subgroup analyses showed that benefits of TEHV are lower 
in older patients (> 80 years), because their lifetime risks on 
events and subsequent re-intervention are lower due to their 
shorter life expectancy.
Due to the high prevalence of aortic valve disease in 
elderly patients, using TEHV instead of bioprostheses 
may lead to costs savings of more than €10 million in the 
next decade in The Netherlands. However, cost savings 
and QALY gains per individual patient were relatively 
low. Higher individual cost savings and QALY gains may 
be achieved when TEHV are used in younger patients as 
more benefits can be gained during their remaining life 
expectancy.
The magnitude of national cost savings depends on per-
spective, substitution rate of TEHV, and patient population 
size. Although TEHV may eventually become the gold 
standard heart valve substitute, it is more likely that sub-
stitution will increase gradually, as observed in the adop-
tion of TAVI in Western Europe where four years after 
introduction only 17.9% of potential candidates underwent 
TAVI [35]. Further, the actual cost savings might be higher 
than reported in this study, because our estimates were not 
adjusted for the expected increase in aortic valve implanta-
tions due to ageing of the general population [2, 6].
Considering the QALY gains TEHV might achieve, 
TEHV may be sold at a higher price and still remain cost-
effective compared to bioprostheses. Depending on TEHV 
performance, the headroom per heart valve substitute 
(assumption: TEHV price is equal to bioprostheses; i.e. 
SAVR: €2500; TAVI: €18,000) varied between €38 and 
€6323 compared with SAVR and €35-€4734 compared with 
TAVI. When we also applied a cost-per-QALY threshold of 
€20.000 for TAVI, the headroom varied between €35 and 
€2367 per heart valve substitute. Instead of assuming the 
price of TEHV is equal to bioprostheses, it may be expected 
that manufacturing costs will be comparable to other inor-
ganic heart valve substitutes (i.e. mechanical valves, €1500). 
Considering these relatively low expected manufacturing 
costs, the results of our headroom analyses are even more 
promising for the commercial viability of TEHV.
External validation of model outcomes with actual sur-
vival and event data from the Providence Health System 
showed that the observed survival was slightly lower than 
the model’s predicted survival. Possible explanations can 
be the slightly lower mean age and considerably higher 
concomitant CABG proportion in patients in the Portland 
dataset compared to the model (Table S16). Survival differ-
ence was larger in females between 70 and 80 years old than 
in other subgroups. This can be explained by comparable 
survival of 70- to 80-year-old females and males in the Port-
land dataset, while a higher survival of females than males 
was applied in the model as observed in the general popu-
lation [18]. Further, cumulative incidence of valve-related 
events was lower in the Portland dataset than in the model. 
Explanations for this discrepancy may be overestimation of 
occurrence of events in the meta-analyses as zero events may 
not be reported in the published literature, underreporting of 
events in the Portland dataset, too short follow-up of patients 
because mean event-free life expectancy in the model was 
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higher than mean follow-up of patients in the Portland data-
set, or differences in outcomes between The Netherlands 
and the US.
Inherent to any early HTA, we had to make assump-
tions regarding costs and clinical performance of TEHV. 
Therefore, this study presents a theoretical exercise and the 
results are a prediction of the potential cost-effectiveness 
of hypothetical TEHV. It is currently uncertain if and when 
TEHV will be introduced in clinical practice and whether 
the performance will indeed be improved compared to 
bioprostheses. However, it is becoming more likely that 
TEHV will have this improved performance, because pre-
clinical and first-in-man clinical trials of TEHV and vascular 
grafts showed promising results and recently a small-scale 
first-in-man clinical trial of tissue-engineered pulmo-
nary valved conduits for children was initiated [10, 
12]. However, there are still several unresolved challenges 
regarding heart valve tissue engineering, including finding 
the optimal material for the scaffold [36], the induction of 
regeneration of functional tissue [9], and finding the optimal 
balance between scaffold degradation and the formation of 
new tissue [9].
There are only a small number of publications on early 
HTA of tissue-engineered therapies. In addition to this anal-
ysis, we also performed an early HTA of TEHV in children 
requiring pulmonary valve replacement (PVR) [37]. The 
cost-effectiveness outcomes are difficult to compare due 
to methodological differences between the analyses, but in 
general, the cost savings associated with TEHV were con-
siderably smaller in elderly requiring SAVR/TAVI than in 
children requiring PVR due to the relatively low probability 
of re-intervention in elderly patients compared to children. 
Furthermore, Tan et  al. performed a cost-minimization 
analysis for comparing tissue-engineered constructs to donor 
tissue procured from eye banks for endothelial keratoplasty 
[38]. They concluded that the tissue engineering strategy 
was cheaper in both investment cost (i.e. costs of the capi-
tal outlay for the necessary equipment) and recurring cost 
(manufacturing cost per construct) [38]. In our study, the 
costs of manufacturing TEHVs were not calculated in detail 
but assumed to be equal to currently used bioprostheses. 
The analysis of Tan et al. suggest, however, that the costs 
of TEHV may be lower, which increases the likelihood of 
TEHV being cost-effectiveness even more.
This study has several limitations. Firstly, we strived to use 
the memory of our patient-level simulation model to make 
survival, valve-related events, utilities and costs dependent on 
patient and intervention characteristics and patient history (i.e. 
previous events). We did indeed do so for early mortality, early 
clinical outcomes, costs and utilities. However, relationships 
between occurrence rates of valve-related events after aortic 
valve implantation on the one hand and patient and interven-
tion characteristics and history of previous valve-related events 
on the other hand remain poorly defined and could, thus, not 
be incorporated into our model. Secondly, the model requires 
assumptions about evolution of event occurrence rates and 
hazard ratio for excess mortality beyond the observed follow-
up period, which introduced uncertainty in the extrapolation 
of these events. Thirdly, most healthcare cost estimates were 
based on health insurances claims data which means that, 
conflicting with the applied societal perspective, costs rep-
resent expenditures reimbursed by health insurers based on 
agreements between healthcare providers and insurers, not 
actual costs. Fourthly, this study was performed from a Dutch 
perspective and may, therefore, not be generalizable to other 
countries. Finally, additional informal care use or productivity 
loss after events, except for stroke and re-intervention, were 
not incorporated due to limited data availability. However, 
additional informal care use and productivity loss of patients 
after hospitalisation for these events are probably relatively 
low and, therefore, will not have a large impact on total costs.
The results of this study can be useful for different stake-
holders. First, we informed engineers about minimum perfor-
mance requirements and maximum additional costs of TEHV 
to be cost-effective compared to bioprostheses early in the 
development process [39]. We showed that engineers should 
primarily focus on durability. Further, a higher price for TEHV 
than bioprostheses is possible. Second, it provides patients and 
clinicians the first estimates of potential improvements in clini-
cal outcomes of TEHV, which may result in faster adoption 
of TEHV in clinical practice [40]. We showed that, although 
benefits of TEHV may be relatively low in elderly patients 
due to their limited remaining life expectancy, TEHV may 
result in improvements in (quality-adjusted) life expectancy 
and reduced costs. Finally, this study informs Dutch healthcare 
payers about the possible entrance of TEHV to the market and 
its associated national cost savings, which may result in more 
timely decisions about reimbursement [40].
In conclusion, when biomedical engineers succeed in realis-
ing improved durability and/or infection resistance of TEHV in 
the aortic position in elderly patients, TEHV have the potential 
to be cost-effective compared to both surgical and transcatheter 
bioprostheses and commercially viable in this patient group. 
Due to the relatively short life expectancy of elderly patients 
undergoing aortic valve implantation, individual cost sav-
ings and QALY gains are relatively meagre, but due to the 
large size of the patient population, national cost savings can 
become substantial.
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